Quantum Biopharma expects data from two now-completed, FDA-requested toxicology studies to support clinical testing of its ...
The festive period brought some unwanted post for both Sanofi and Corcept Therapeutics in the form of FDA rejections for the ...
England's NICE is recommending natalizumab, sold as Tysabri and Tyruko, as an NHS-covered treatment option for people with ...
The team, consisting of researchers from University College London (UCL) and Queen Square Analytics, analysed 634 patients ...
Two new sub-types of multiple sclerosis (MS) were discovered by researchers from Queen Square Analytics and University ...
Hosted on MSN
Biomarker provides clear criteria for choice of treatment options in multiple sclerosis
Treatment with interferon or with glatiramer acetate? This question arises for many patients who receive a diagnosis of multiple sclerosis (MS) for the first time. Until now, the choice between the ...
Prof Nicholas Schwab and his colleagues found a biomarker which allows to tell in advance if therapy with glatirameracetate will be efficient in an individual MS patent. Treatment with interferon or ...
New research led by NYU Langone Medical Center examines what happens when a patient with multiple sclerosis (MS) who is clinically stable stops taking their medication. The international, multi-site ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback